Currently, there are 666.10M common shares owned by the public and among those 426.71M shares have been available to trade.
The company’s stock has a 5-day price change of 14.81% and -0.32% over the past three months. CLVT shares are trading -33.05% year to date (YTD), with the 12-month market performance down to -12.80% lower. It has a 12-month low price of $4.97 and touched a high of $9.60 over the same period. CLVT has an average intraday trading volume of 4.86 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -1.82%, 5.27%, and -14.24% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Clarivate Plc (NYSE: CLVT) shares accounts for 59.17% of the company’s 666.10M shares outstanding.
It has a market capitalization of $4.49B and a beta (3y monthly) value of 1.21. The earnings-per-share (ttm) stands at -$1.91. Price movements for the stock have been influenced by the stock’s volatility, which stands at 9.24% over the week and 6.19% over the month.
Earnings per share for the fiscal year are expected to decrease by -9.72%, and 6.96% over the next financial year. EPS should shrink at an annualized rate of 1.30% over the next five years, compared to 60.20% over the past 5-year period.
Looking at the support for the CLVT, a number of firms have released research notes about the stock. Wells Fargo stated their Underweight rating for the stock in a research note on December 15, 2023, with the firm’s price target at $8. Jefferies coverage for the Clarivate Plc (CLVT) stock in a research note released on October 16, 2023 offered a Buy rating with a price target of $8.50. Barclays was of a view on September 08, 2023 that the stock is Underweight, while RBC Capital Mkts gave the stock Sector Perform rating on August 25, 2023, issuing a price target of $9- $8. BofA Securities on their part issued Underperform rating on August 07, 2023.
